EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological MRI : Utility in Understanding Drug Mechanisms in Psychiatric Disorders

Christin Y Sander, Tudor M Ionescu, Mitul A Mehta, Ottavia Dipasquale, Anouk Schrantee iD

Journal of Magnetic Resonance Imaging · 2026-02 · 63 (2) · 346-363

DOI: 10.1002/jmri.70160 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Magnetic Resonance Imaging, online erschienen am 29.10.2025. Verfasst von Christin Y Sander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts, USA. Hauptthemen laut MEDLINE: Mental Disorders, Magnetic Resonance Imaging, Brain, Psychotropic Drugs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDA NIH HHS, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacological MRI (pharmaMRI) has emerged as a powerful tool to study how psychoactive drugs affect brain function and to uncover mechanisms of drug action in psychiatric disorders. This review provides an overview of key techniques used in pharmaMRI, including BOLD‐fMRI, arterial spin labeling (ASL), and cerebral blood volume (CBV) mapping, and how they have advanced our understanding of drug‐induced changes in neural activity and connectivity. We present key advances in both preclinical and clinical pharmaMRI, highlighting its value in elucidating drug mechanisms and informing psychiatric treatment development. In preclinical studies, pharmaMRI benefits from optimized hardware, the use of contrast agents such as iron oxide nanoparticles, and precise experimental control, including invasive neuromodulation techniques (e.g., opto‐ and chemogenetics). These studies offer critical mechanistic insights into receptor‐specific and circuit‐level drug effects, supporting hypothesis‐driven translation to humans. Clinically, pharmaMRI has advanced our understanding of how compounds, such as antidepressants, antipsychotics, and stimulants, affect large‐scale brain networks and offers potential for modeling psychiatric phenotypes and predicting treatment response. Furthermore, pharmaMRI can serve as a biomarker for target engagement and refine dose selection in early‐phase trials. Despite growing interest, clinical adoption remains limited. Systematic use of both preclinical and clinical pharmaMRI could accelerate drug development, support precision psychiatry, and deepen understanding of treatment mechanisms. Finally, open science practices and large‐scale datasets can help contextualize drug effects within broader neural and molecular frameworks. While these developments present some challenges, they position pharmaMRI as a critical bridge between molecular mechanisms and systems‐level brain function in psychiatry. Evidence Level N/A. Technical Efficacy Stage 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mental DisordersMagnetic Resonance ImagingBrainPsychotropic DrugsHumansAnimalsBrain MappingSpin Labels

Stichwörter der Autor:innen

animal modelsfunctional imagingpharmacological MRIprecision psychiatrypsychotropic drugs

Substanzen

Psychotropic DrugsSpin Labels

Autor:innen und Institutionen

  • Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neuroscience and Mental Health Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Department of R&D Advanced Applications, Olea Medical, La Ciotat, France.
  • Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Anouk Schrantee

Förderung

  • NIH HHS
  • NIDA NIH HHS
  • ZonMw
  • National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC)
  • National Institutes of Health
  • NIHR Maudsley Biomedical Research Centre

Zitieren

APA

Sander, C. Y., Ionescu, T. M., Mehta, M. A., Dipasquale, O., & Schrantee, A. (2026). Pharmacological MRI : Utility in Understanding Drug Mechanisms in Psychiatric Disorders. Journal of Magnetic Resonance Imaging, 63(2), 346-363. https://doi.org/10.1002/jmri.70160

Vancouver

Sander CY, Ionescu TM, Mehta MA, Dipasquale O, Schrantee A. Pharmacological MRI : Utility in Understanding Drug Mechanisms in Psychiatric Disorders. Journal of Magnetic Resonance Imaging. 2026;63(2):346-363. doi:10.1002/jmri.70160

BibTeX
@article{Sander2026,
  author = {Sander, Christin Y and Ionescu, Tudor M and Mehta, Mitul A and Dipasquale, Ottavia and Schrantee, Anouk},
  title = {Pharmacological MRI : Utility in Understanding Drug Mechanisms in Psychiatric Disorders},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2026},
  volume = {63},
  number = {2},
  pages = {346--363},
  doi = {10.1002/jmri.70160}
}
Kostenlos starten →